Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805894 · ClinicalTrials.gov registry record · Phase 1
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
A Phase 1 study, sponsored by Nanobiotix.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02805894: Clinical Trial Phase 1 study, sponsored by Nanobiotix.
NCT02805894 is a Phase 1 study that was terminated before completion, run by Nanobiotix. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02805894, a Phase 1 study, was terminated before completion, sponsored by Nanobiotix.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both groups will receive treatment with androgen deprivation. There will be 2 consecutive steps, a dose escalation and a subsequent dose expansion part.
Interventions
- DRUG NBTXR3 activated by IMRT only
- DRUG NBTXR3 activated by Brachytherapy & IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2020-03-19 |
| Phase | Phase 1 |
Why NCT02805894 stopped before completion
NCT02805894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which NBTXR3 activated by IMRT only is the first listed.
NCT02805894 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02805894 about?
NCT02805894 is a clinical study titled "NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma". This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both groups will receive treatment wit...
What is the current status of trial NCT02805894?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-11-15. Estimated completion is 2020-03-19.
What interventions are being tested in trial NCT02805894?
The interventions under investigation include: NBTXR3 activated by IMRT only (DRUG), NBTXR3 activated by Brachytherapy & IMRT (DRUG).
Who is sponsoring clinical trial NCT02805894?
This trial is sponsored by Nanobiotix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02805894's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI